Wuxi pharmatech merger wave of change banner from non-clinical cro

WuXi PharmaTech Was acquired. "WUXI" Zeng Yin WuXi PharmaTech's English name "WUXIAppTec" European and American bio-technology has been widely known, but in the future will be "CRL" replaced. According to public sources, the world's largest pre-clinical experiments supplier?? CRL (CharlesRiverLaboratoriesInternationalInc),South Africa soccer jerseys, agreed to about 16 million (equivalent to 10.9 billion yuan) of the purchase price to the company China's largest CRO WuXi PharmaTech income capsule. "China will continue to retain the name of WuXi PharmaTech, China's business still all the company to operate." WuXi PharmaTech, Founder and CEO Ge Li told " Medicine Economic News "reporter. Signal change to the Joint Research "This acquisition will change the pattern of the industry to promote small and medium sized companies and professional services to the specific direction, together with large companies forming a more perfect system of drug research and development of innovative services to a new level of CRO meaning, the contract research organization (ContractResearchOrganization) into a joint research organization (CollaborativeResearchOrganization). " Roche (Shanghai) R & D Chief Scientific Officer Chen Li of China in this field of medicine from the date of acquisition the largest response,Atletico Madrid Jerseys, and Pharmacy As the industry trend of mergers and reorganizations, the services derived from the drug development industry is also integrated. WuXi PharmaTech's official website revealed that the combined company still CRL name,Sanderland jerseys, and multinational pharmaceutical, biotechnology and medical device companies, as well as academic institutions and government agencies to provide outsourcing services and products. According to the information, CRL Chairman of the Board,authentic soccer jerseys, President and CEO JamesC.Foster will continue to lead the combined company, Li Ge will serve as executive vice president and the subordinate service global drug discovery and the Chinese president, who will as our new independent accounting department. In addition, two other Ge Li, WuXi PharmaTech and directors will join the CRL Board of Directors. CRL annexation of WuXi PharmaTech's news on Wall Street did not cause a small vibration. "If WuXi PharmaTech to be acquired, CRL is the best buyers." Novartis (China) Co., Ltd. Biomedical Research Director, Xiang-Yang L�� biological research and development told reporters. "Because the two companies in the outsourcing business is highly complementary to each other, the future integration does not exist too many obstacles." According to Xiang-Yang L�� introduction, Novartis and WuXi PharmaTech, CRL also launched Cooperation In the contract with WuXi PharmaTech orders concentrated in chemical synthesis and biological markers, and more cooperation with CRL on the field of animal toxicological experiments. Morgan Stanley on April 26 of the quick assessment that the acquisition of WuXi PharmaTech's shareholders benefit because the transaction will eliminate WuXi PharmaTech business in the field of toxicology and industrial uncertainty, the current This business is WuXi PharmaTech two weak links, require significant capital expenditure. Ability to complement chemical synthesis and Toxicology In March 2007 to enter China's CRL, established in Shanghai Zhangjiang Medicine Valley, a 50,000 square meters of pre-clinical laboratory, and was from 2008 to 2009 began operating in providing,Soccer jersey, including GLP and non- GLP toxicity studies of a variety of drug development services. "But they lack the chemical synthesis of this paragraph." Xiang-Yang L�� said. , Created in 2000, WuXi PharmaTech has always been good at exploring new drugs of chemical services, is also the story of the rise of the industry relish. I am a professional writer from , which contains a great deal of information about , , welcome to visit!